Iron Indices and Intravenous Ferumoxytol: Time to Steady State

Inclusion Criteria: * Chronic hemodialysis subjects who have received dialysis treatment for more than 90 days * TSAT less than or equal to 25 percent * Serum ferritin less than or equal to 200 nanograms/milliliter (ng/mL) * (Female) Subjects are willing to use reliable contraception, or have undergone menopause (chemical or surgical) * Subjects who are able to read and write in English * Subjects who have signed consent Exclusion Criteria: * Subjects who have been enrolled in a clinical trial within the past 30 days * Subjects who have received IV iron within 4 weeks of the start of the study * Serum ferritin greater than or equal to 1200 ng/dL * Hemoglobin (Hb) less than 10 grams/deciliter (g/dL), or greater than 13.5 g/dL * Evidence of iron overload * Known hypersensitivity to ferumoxytol or any of its components * Anemia caused by conditions other than iron deficiency * Subjects with elective surgeries scheduled within the next 3 months * Subjects with elective magnetic resonance procedure scheduled during the study period * Subjects who have been hospitalized within the past 30 days (excluding vascular access care) * Subjects who have received a blood transfusion in the past 30 days * Subjects who are transfusion dependent * (Female) Subjects who are pregnant or nursing * Subjects with known inflammatory conditions which may affect serum ferritin * Subjects who are considered to be clinically unstable at the discretion of Principal Investigator (P.I.) * Subjects who have a clinically unstable blood pressure (BP) of systolic greater than 180 millimeters of mercury (mmHg) and/or diastolic greater than 100 mmHg (sitting, pre-dialysis) * Subjects with life expectancy less than 6 months * Subjects who refuse to sign consent